Spectrum appoints Lenaz new lead director

Spectrum Pharmaceuticals' Dr. Luigi Lenaz has been appointed the new lead director, a position recently created by the company.
Spectrum specializes in biotechnology that acquires, develops and commercializes drug products and dedicates the majority of its time to hematology and oncology.
“Dr. Lenaz’s unique scientific background and deep business expertise make him ideally suited for the newly created Lead Director position,” Spectrum Pharmaceuticals Chairman and CEO Dr. Rajesh Shrotriya said. “Dr. Lenaz has provided invaluable advice historically, and I look forward to working closely with him in his new role.”
Lenaz is known throughout the world as an oncologist and a leading authority when it comes to the development of medications to help combat cancer. Prior to joining the industry, he was already an accomplished oncologist. He has worked with a number of prominent institutions including Roswell Park Memorial Institute, Memorial Sloan-Kettering Cancer Center and the National Cancer Institute in Milan, conducting his research at each. Lenaz has worked in the pharmaceutical industry for more than 40 years and has abundant experience when it comes to the development of anti-cancer medications.